SUMMARY Two patients with low random serum vitamin K, concentrations but with normal prothrombin times and normal biological assays of the vitamin K dependent coagulation proteins were treated with an N-methyl-thiotetrazole cephalosporin (cefotetan) postoperatively. Four to six days later both patients developed a prolonged prothrombin time and a noticeable and specific lowering of the clotting activities of factors II, VII, IX and X, though the serum vitamin K, concentrations remained unchanged. Crossed immunoelectrophoresis of prothrombin showed the appearance of a second peak corresponding to descarboxyprothrombin (PIVKA II). These abnormalities corrected after vitamin K administration. These data are consistent with the hypothesis that cephalosporins with an N-methyl-thiotetrazole side chain inhibit the hepatic utilisation of vitamin K but that this only causes hypoprothrombinaemia when liver reserves of vitamin K are low.
amoxef,2 3 cefamandole,4 and cefoperazone.' These events occurred most in patients with renal failure, those who are severely malnourished with chronic gastrointestinal disease, or those who had been receiving prolonged parenteral nutrition.6 It has been suggested that NMTT cephalosporins may cause vitamin K deficiency by suppressing the vitamin K producing micro-organisms of the colonic microflora.78 Contradicting this hypothesis is the lack of evidence that menaquinones (vitamin K2) can be absorbed from the colon and the fact that other antibiotics such as tetracyclines, which also strongly suppress the bowel flora, are not known to be associated with vitamin K deficiency. Another hypothesis is that the NMTT side chain directly inhibits the vitamin K dependent y-carboxylation of clotting factors in the liver cell. 9 10
Cefotetan (ICI) is a new compound in the cephamycin subdivision of the cephalosporins with an Accepted for publication 21 May 1986 NMTT side chain. " We investigated the effects of this new cephalosporin on vitamin K, metabolism and hepatic synthesis of the vitamin K dependent coagulation factors after parenteral nutrition given over several days to two patients with a normal prothrombin time and normal factor II, VII, IX and X assays before treatment. Both patients, however, had subnormal serum vitamin K, concentrations before treatment was started.
Patients CASE 1
An 81 year old woman presented with a two month history of generalised abdominal pain and vomiting over the previous week. On admission (day 1), a diagnosis of a strangulated left femoral hernia was made and operative repair was carried out that day. Prophylactic antibiotic cover was started with intravenous cefotetan (2 g) given every 12 hours; treatment was continued for four days. She gave a history of recent weight loss, but routine liver function and renal function tests were within normal limits. On day four, after six doses of cefotetan, treatment was stopped and 10 mg of vitamin K, was given intramuscularly later that day when the prothrombin time was found to be prolonged. Tables I and 2 show the results of assays for plasma coagulation factors and serum vitamin K,. Before treatment with antibiotics both patients had normal prothrombin times (13-7 and 13-7 seconds, normal range 12-14 seconds) and normal activities in the biological assays for the vitamin K dependent clotting factors II, VII, IX and X, but serum concentration of vitamin K1 (54 and 78 pg/ml) were substantially reduced compared with those in the range (170-680 pg/mI) in 45 normal fasting adults using the same electrochemical method. After four and six days of treatment with cefotetan the serum vitamin K, concentrations remained unchanged (52 and 73 pg/mI), but both patients developed a severe hypoprothrombinaemia, evidenced both by an increased prothrombin time (34.7 and 20-5 seconds) and clotting assays that showed a specific lowering of the four vitamin K dependent factors. Hypo- 
severe in the patient having the lower serum vitamin K1, a serum concentration that was less than one third the lower limit of the normal range. In this patient the reduction in clotting factors was most noticeable for factors VII and IX (half lives four to six hours and 24 hours, respectively) than for factors X and II, which have longer circulating half lives (48 hours and 60 hours, respectively). Over the same period the clotting activity of factor V, which is also synthesised in the hepatocyte but is not a vitamin K dependent protein, did not change appreciably in either patient. Factor II activity measured by the Ecarin method and factors II and IX antigenic activity, however, did not change in either patient. The Ecarin assay measured both descarboxyprothrombin (PIVKA-II) and the biologically active fully y-carboxylated prothrombin: the similar values before and after treatment with cefotetan indicate that the fall in biological activity of factor II is due to an impaired vitamin K dependent y-carboxylation rather than an impaired hepatic synthesis of the core protein. This was confirmed by crossed immunoelectrophoresis, which showed the characteristic faster migrating peak of noncarboxylated species of prothrombin after treatment with cefotetan and a single peak of normal prothrombin before treatment (case 1) (figure). Similar findings were found in case 2 by crossed immunoelectrophoresis (results not shown).
The effect of 10 mg of vitamin K, given by intramuscular injection was most noticeable, producing after 12 to 24 hours a substantial normalisation of the prolonged prothrombin time and increased circulating concentration of biologically active vitamin K dependent factors.
Discussion
Vitamin K deficiency is usually identified by the presence of a prolonged prothrombin time that corrects after vitamin K administration. In vitamin K deficiency, or in the presence of vitamin K antagonists (such as the coumarin anticoagulant warfarin), the postribosomal y-carboxylation of certain glutamic acid residues of the vitamin K dependent clotting fac- A feature of the investigations in these two patients was the measurement of their plasma concentrations of vitamin K, (phylloquinone). Until recently, such measurements have been hampered by the analytical problems associated with the detection of the low circulating concentrations in blood: consequently, very little is known about plasma concentrations of vitamin K in health and disease and nothing about those concentrations that may relate to an overt or marginal deficiency of vitamin K. Using a recently developed assay, based on high performance liquid chromatography with electrochemical detection'2 but refined for use with an internal standard, the normal range of plasma vitamin K, in 45 healthy fasting adults was 170-680 pg/ml (median 372, mean 412 pg/ml). The plasma values of vitamin K1 in the patients (54 and 52 pg/ml in case 1, 78 and 73 pg/mI in case 2) were notable in several respects. Firstly, they were well below the normal range; secondly, they did not change during the period of the study and; thirdly, although low, the plasma vitamin K1 was sufficiently high to maintain normal plasma concentrations of the vitamin K dependent clotting factors until they were treated with cefotetan. The relation between plasma concentrations of vitamin K1 and tissue reserves remains to be established, but it seems reasonable to assume that, as with other fat soluble vitamins, low plasma concentrations reflect low body stores. It is likely, therefore, that both these patients had low vitamin K reserves in the liver, which is the site of synthesis of the vitamin K dependent clotting factors. Both patients had a chronically poor nutritional state, and in the week or so before hospital admission, their dietary intake had further diminished due to generalised abdominal pain and vomiting.
It has previously been suggested that cephalosporins containing the NMTT side chain such as latamoxef and cefamandole cause prolongation of the prothrombin time by inhibiting the action of the vitamin K 2,3-epoxide reductase enzyme."9 This would seem to occur after in vivo degradation of the antibiotic and release of the NMTT side chain. 9 patients with chronic gastrointestinal malabsorption states24 is cefotetan likely to inhibit the vitamin K oxidation reduction cycle and cause decreased y-carboxylation of the K dependent proteins. Obviously in patients receiving warfarin and antibiotics with a cephalosporin containing the NMTT side chain, there is a risk of a synergistic reaction with a sudden decreased y-carboxylation of the vitamin K dependent factors and excessive prolongation of the prothrombin time.
Although both these patients developed a prolonged prothrombin time, neither had any clinical bleeding episode or spontaneous bruising. Other NMTT containing cephalosporins, particularly latamoxef2 3 have often been associated with a clinical bleeding diathesis. These antibiotics, as well as inhibiting the vitamin K epoxide-reductase activity; also appreciably inhibit platelet function and prolong the bleeding time at standard therapeutic doses.25 Cefotetan does not inhibit platelet function or prolong the bleeding time21 and is thus much less likely to cause bleeding events.
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